Triple-Therapie bei Koronarinterventionen und Indikation zur oralen Antikoagulation

Abstract

The current antithrombotic therapy recommendation for patients on oral anticoagulation who undergo coronary stenting consists of a triple therapy with aspirin, clopidogrel and a vitamin K antagonist. As the data on triple therapy derives mainly from observational studies and only one randomized trial, the level of evidence is low however. This review reflects recent developments in the setting of triple therapy including choice of (i) newer P2Y12 blocker (prasugrel, ticagrelor), (II) new oral anticoagulants (dabigatran, rivaroxaban, apixaban), (iii) drug eluting vs. bare metal stents and (iv) use of aspirin.

• Literatur

• 1 Schomig A, Sarafoff N, Seyfarth M. Triple antithrombotic management after stent implantation: when and how?. Heart 2009; 95: 1280-1285
• 2 Rubboli A, Halperin JL, Juhani Airaksinen KE et al. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med 2008; 40: 428-436
• 3 Hansen ML, Sorensen R, Clausen MT et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010; 170: 1433-1441
• 4 Dewilde WJ, Oirbans T, Verheugt FW et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet 2013; 381: 1107-1115
• 5 Lamberts M, Olesen JB, Ruwald MH et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012; 126: 1185-1193
• 6 Sarafoff N, Holmes Jr DR. UpToDate: Triple antithrombotic therapy in patients with cardiovascular disease. 2013 Im Internet: www.uptodate.com/contents/triple-antithrombotic-therapy-in-patients-with-cardiovascular-disease Stand: 01.08.2013
• 7 Zhao HJ, Zheng ZT, Wang ZH et al. „Triple therapy“ rather than „triple threat“: a meta-analysis of the two antithrombotic regimens after stent implantation in patients receiving long-term oral anticoagulant treatment. Chest 2011; 139: 260-270
• 8 Sarafoff N, Martischnig A, Wealer J et al. Triple therapy with aspirin, prasugrel and vitamin K antagonists in patients with drug eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol 2013; 61: 2060-2066
• 9 Dans AL, Connolly SJ, Wallentin L et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. Circulation 2013; 127: 634-640
• 10 Bayer AG Investor Relations. Neue Studie mit Xarelto (Rivaroxaban) von Bayer bei Patienten mit nicht-valvulärem Vorhofflimmern, die sich einer perkutanen Koronarintervention mit Stenteinsatz unterziehen. Leverkusen: 2013 Im Internet: www.investor.bayer.de/news/investor-news/investor-news/showNewsItem/1545/1362745620/f7b5a77390 Stand: 01.08.2013
• 11 Camm AJ, Kirchhof P, Lip GY et al. Guidelines for the management of atrial fibrillation: The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J 2010; 31: 2369-2429